Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
BOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing...
Pharmaceutical
IntegriChain Revenue Optimization Experts to Speak at Informa’s Pharma/BioTech GTN Summit
PHILADELPHIA, Nov. 11, 2024 /PRNewswire/ -- IntegriChain, the leading provider of pharma revenue optimization technology and insights for the pharmaceutical...
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients...
GE HealthCare and RadNet Forge Collaboration to Transform Imaging Systems and Accelerate the Adoption of Artificial Intelligence (AI) with SmartTechnology™
Collaboration will leverage GE HealthCare’s legacy and scale of imaging innovation and RadNet’s DeepHealth AI-powered clinical and workflow solutions to...
CardioComm Solutions Integrates ECG Technology into Sony’s mSafety Platform
Collaboration Brings Advanced ECG Monitoring to Sony's Wearable Health SolutionToronto, Ontario--(Newsfile Corp. - November 11, 2024) - CardioComm Solutions, (TSXV:...
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
Click here to register for investor webcastCompany plans to file its Earnings Report on November 13, 2024 on Form 10-Q...
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
IRB approval on track as scheduledNext step is obtaining all regulatory approvals, followed by site initiation visitVELDONA significantly increases unstimulated...
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosingDose-dependent exposure was observed with evidence of...
Inozyme Pharma to Present at Upcoming Investor Conferences
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company...
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of...
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
KIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a...
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer...
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual Scientific Sessions
DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present...
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunitiesSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024...
Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
Institutional Investment of £600,000Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials LONDON, UNITED KINGDOM / ACCESSWIRE / November 11,...
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical...
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS...
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected...
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort...
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish...